Evercore ISI initiated coverage of Penumbra (PEN) with an Outperform rating and $300 price target As the “leading thrombectomy player” in the neurovascular segment, Penumbra is set to accelerate its topline growth heading into FY26 as China headwinds clear and new products launch, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra Appoints Shruthi Narayan as New President
- Penumbra’s Strategic Growth Initiatives and Market Expansion Drive Buy Rating
- Penumbra’s Strong Growth Potential and Strategic Developments Reinforce Buy Rating
- Penumbra Inc. Reports Strong Q2 Earnings with Growth in U.S. Thrombectomy
- Penumbra price target raised to $310 from $300 at Truist